There is no cooling in Venus Freeze. The name is a trademark, not a description. The device delivers multipolar radiofrequency together with pulsed electromagnetic fields. It heats tissue rather than chilling it. If you came to this comparison expecting two fat-freezing machines, only one of them freezes anything.
Venus Freeze is not cleared for fat, and not for body contouring either. It holds two FDA clearances: K100586 from 29 November 2010 and K111670 from 2 March 2012. Both are for the non-invasive treatment of facial wrinkles and rhytides, meaning lines in the skin. Neither mentions fat, lipolysis, circumference or any body area below the neck.
CoolSculpting's clearance is the opposite in every respect. It covers cold-assisted lipolysis, meaning breakdown of fat, of seven named body regions in people with a body mass index of 30 or less. It also covers the areas under the chin and jaw, up to a body mass index of 46.2.
The name is the most useful thing this page can warn you about, because it does the misleading on its own. Venus Concept does hold real body-fat clearances in the US. They belong to a different product line, Venus Bliss, which uses a diode laser. Those clearances are not Venus Freeze's. A clinic quoting you for "Venus Freeze" for your abdomen is quoting you for a facial wrinkle device used off its clearance.
It holds two clearances, K100586 and K111670. A 510(k) clearance is a finding that a device is much the same as one already on the market. It is not a finding that it works.
It was authorised through De Novo request DEN090002, decided 24 August 2010. That request created the FDA category for cryolipolysis.
Fat cells are more easily harmed by cold than skin, nerve and blood vessel. The injured cells die off, and the immune system clears them over the following weeks. Cleared settings are specific: minus 10 degrees Celsius for 60 minutes under the chin, and minus 11 degrees for 35 minutes on the upper arm.
That is the whole of it, in the FDA's own words, across both clearances. No fat. No lipolysis. No circumference. No body area at all. The wording says facial.
The submental and submandibular areas are cleared separately, up to a body mass index of 46.2. Under the chin, the device is also cleared to affect the appearance of lax tissue. CoolSculpting Elite is K212707, cleared 5 November 2021.
Scope that to this device. Radiofrequency as a technology does have a body-contouring literature. Other makers hold radiofrequency clearances that name fat. But that evidence was built on other machines and belongs to them.
Single studies spanned 10.3% to 25.5%. An independent randomised split-body trial in 2023 measured about 14%. All of these describe the thickness of a pinched fat layer at one point.
Pain that arrives several days late is common. A review of 554 procedures found it lasted 3 to 11 days and cleared on its own.
The mean was 5.6 cycles and 1.9 sessions. Results were checked at 12 or 16 weeks in the FDA-reviewed trials.
Nothing citable exists from a professional society or a consumer aggregate. Any range you see is one clinic's own.
Those reviewers rated it 59% "Worth It". The American Society of Plastic Surgeons' last published average physician fee for non-surgical fat reduction was $1,157, for 2023. That is a category average across six unrelated products, not a CoolSculpting price. No such fee was published in 2024 at all.
"Freeze" here is branding. The device produces heat, not cold. There is no cryolipolysis in it, and no cooling applicator. Searches for "Venus Freeze vs CoolSculpting" almost always come from someone who assumes they are comparing two fat-freezing options. That assumption is wrong at the first step.
The practical consequence is that what you have read about cryolipolysis does not transfer to Venus Freeze: That covers the mechanism, the timeline, the risks and the paradoxical lump. None of the physics is the same. And what you may have read about radiofrequency body contouring belongs to other makers' machines, with their own clearances and their own trials.
Both Venus Freeze clearances sit under a general dermatology product code, and both describe facial work. The 2010 clearance reads as a non-invasive device for use in dermatologic and general surgical procedures, for the non-invasive treatment of mild to moderate facial wrinkles and rhytides. The 2012 clearance for the (MP)² system reads the same way for moderate to severe facial wrinkles, in females, in Fitzpatrick skin types I to IV.
Read those twice and note what is missing. There is no body area, no fat, no lipolysis, no circumference, and no cellulite. A device used on an abdomen or thighs under those clearances is being used outside them.
That is legal. Clinicians may lawfully use a cleared device outside its cleared indication, because the FDA regulates makers' claims rather than the practice of medicine. But it means the evidence the FDA reviewed does not cover what is being done. Neither does the maker's safety data. You are entitled to be told which side of that line you are on.
This is where it gets easy to get confused, so it is worth being exact. Venus Bliss was cleared as K190743 on 25 June 2019. It is cleared to treat non-invasive lipolysis of the abdomen and flanks, in people with a body mass index of 30 or less. That fat claim rests on a diode laser, not on radiofrequency. The same clearance separately carries the radiofrequency-and-massage applicator claims: relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation, and temporary reduction in the appearance of cellulite. Later clearances for Venus BlissMAX repeat that structure and add muscle-stimulation applicators.
So the company holds a genuine, narrow, abdomen-and-flanks fat clearance. It belongs to a different machine, and it belongs to the laser inside that machine. It does not belong to Venus Freeze.
For Venus Freeze in body fat, nothing has been published that could be found. There is no measured fat-layer change, no circumference figure, no follow-up duration, and no session count from a primary source. Anything quoted to you is either about a different device or about nothing in particular.
For CoolSculpting there is a real body of measurement, and it deserves the same honesty. The main endpoint in most of its clearances is blinded photo identification. That asks whether reviewers can pick the "before" picture better than chance, with a pass mark of 80%. The pivotal under-chin study, run by the manufacturer, hit 91%. That tells you trained observers can tell the pictures apart. It does not tell you how much fat went, and it does not tell you what you will see in a mirror. The fat-layer numbers sit underneath as secondary measurements, in the range of two to three millimetres in most studies. Nobody has ever published a threshold for how much change a person can notice.
The FDA's body-contouring page, last updated 15 October 2025, says non-invasive body contouring "does not treat obesity or improve your health. It will not result in weight loss." CoolSculpting's own maker safety information says the procedure is not a treatment for weight loss, and does not replace diet, exercise or liposuction. The body mass index figures written into the clearance are a ceiling on who may be treated. They are not something the treatment is designed to move. No professional society has published a formal position statement saying so. The regulator and the maker are where that framing comes from.
Ask directly whether the area being treated is inside the device's cleared indication: For Venus Freeze on a body area, the answer is no. Knowing that in advance is more useful than finding it out afterwards.
Disclose a pacemaker, implanted defibrillator, or any metal or electronic implant near the treatment area before a radiofrequency treatment: These are labelled exclusions for radiofrequency devices. They are set as a precaution rather than tested. The team who manage the implant are the right people to advise you.
For cryolipolysis, disclose the three cold-related blood disorders that rule it out completely: They are cryoglobulinemia, cold agglutinin disease and paroxysmal cold hemoglobinuria. They look like unrelated jargon, but they share one thing: blood that reacts badly to cold.
Mention a hernia at or near the treatment site, including a repaired one: It appears in the FDA's risk list for this whole device class, and in CoolSculpting's own precautions.
Also worth disclosing: cold urticaria, Raynaud's or chilblains, reduced feeling or circulation in the area, bleeding disorders or blood thinners, recent surgery or scarring at the site, and eczema or dermatitis over the area.
Fever or chills after treatment
Redness spreading outward from the treated area hour by hour
Pus or discharge from treated skin
These are signs of a spreading infection and need urgent care the same day.
A firm, well-defined lump appears in a CoolSculpting-treated area two to six months later, above all if it matches the applicator's shape. This is paradoxical adipose hyperplasia. It does not clear up on its own, and repeat cryolipolysis to the area has been reported to make it worse
Pain or swelling is rising after day three rather than settling
Numbness in the treated area is still there after about three months
A burn, blister or open area appears - acute skin damage, dyspigmentation, infection and scarring are among the events reported for devices in this class in the FDA's adverse event database, which is voluntary and has no denominator
The treated skin darkens a lot over the following weeks
The area looks hollow or dented next to the untreated side